Role of iron in pathophysiology of MDS, in a preclinical model by Ada Antypiuk et al.
Talha Badar, a Specialist in Hematology Oncology based at Mayo Clinic, shared a post on X about a recent paper by Ada Antypiuk,
“Role of iron in pathophysiology of MDS, in a preclinical model.
Iron restriction improves erythropoiesis, limits myeloid expansion, and delays leukemia transformation.”
Authors: Ada AntypiukZebulon VanceRicha SharmaSara PassosMichela Aspertihobana NavaneethabalakrishanFranz DürrenbergerVania ManolovaFrancesca Vinchi.
Dr. Talha Badar, MD, is a specialist in Hematology Oncology based in Mayo Clinic, Jacksonville, Florida. His primary areas of expertise include Leukemia, particularly Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplantation. Over his career, he has actively contributed to clinical research and clinical trials.
More posts featuring Talha Badar.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023